NEW ORLEANS, July 31, 2024 (GLOBE NEWSWIRE) -- ClaimsFiler, a FREE shareholder information service, reminds investors that they have until September 24, 2024 to file lead plaintiff applications in a securities class action lawsuit against MacroGenics, Inc. (or the "Company") (NasdaqGS: MGNX), if they purchased the Company's shares or sold the Company's puts between March 7, 2024 to May 9, 2024, inclusive (the "Class Period"). This action is pending in the United States District Court for the District of Mar ...

MacroGenics Inc. MGNX announced on Tuesday that it reviewed data accumulated from the TAMARACK Phase 2 study of vobramitamab duocarmazine (vobra duo). In May, when the company released interim data from the trial, MacroGenics reported five deaths (fatal outcome) during the trial. After reviewing, MacroGenics agreed with the study's Independent Data Monitoring Committee's recommendation to discontinue the treatment for the remaining metastatic castration-resistant prostate cancer (mCRPC) study participants w ...

NEW YORK, July 31, 2024 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in MacroGenics, Inc. ("MacroGenics" or the "Company") (NASDAQ: MGNX) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of MacroGenics investors who were adversely affected by alleged securities fraud between March 7, 2024 and May 9, 2024. Follow the link below to get more information and be contacted by a member of our team: https://zlk.com/pslra-1/macrogenics-inc-lawsuit- ...

Macrogenics (NASDAQ:MGNX) stock is dropping on Wednesday as the biopharmaceutical company prepares to discontinue a clinical trial of vobramitamab duocarmazine. How This Affects MGNX Stock On the date of publication, William White did not have (either directly or indirectly) any positions in the securities mentioned in this article. The opinions expressed in this article are those of the writer, subject to the InvestorPlace.com Publishing Guidelines. Scott Koenig, M.D., Ph.D., president and CEO of MacroGeni ...

SAN DIEGO, July 30, 2024 (GLOBE NEWSWIRE) -- Robbins LLP informs investors that a shareholder filed a class action on behalf of all persons and entities that purchased or otherwise acquired MacroGenics, Inc. (NASDAQ: MGNX) common stock between March 7, 2024 and May 9, 2024. MacroGenics is a biopharmaceutical company focused on discovering, developing, manufacturing, and commercializing innovative monoclonal antibody-based therapeutics for the treatment of cancer. The Allegations: Robbins LLP is Investigatin ...

Core Insights - MacroGenics announced five fatal outcomes in its TAMARACK Phase 2 study of vobramitamab duocarmazine for metastatic castration-resistant prostate cancer, leading to a significant decline in share price [1] - The share price dropped by $11.36, or approximately 77.4%, from $14.67 on May 9, 2024, to close at $3.31 on May 10, 2024 [1] Legal Actions - A class action lawsuit has been filed against MacroGenics in the United States District Court for the District of Maryland, representing all individuals and entities who acquired MacroGenics securities between March 7, 2024, and May 9, 2024 [4] - Investors have until September 24, 2024, to apply to be appointed as lead plaintiff in the lawsuit [4] - The lawsuit alleges that MacroGenics made material misrepresentations by providing overly positive statements while concealing adverse facts related to early interim safety data from the TAMARACK Phase 2 study [6]

NEW YORK, July 30, 2024 (GLOBE NEWSWIRE) -- SO WHAT: If you purchased stock or sold puts of MacroGenics during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement. DETAILS OF THE CASE: According to the lawsuit, throughout the Class Period, defendants provided overwhelmingly positive statements to investors while, at the same time, disseminating materially false and misleading statements and/or concealing material adver ...

Abstract of clinical data accepted for poster presentation at ESMO Congress 2024 in September ESMO poster to include protocol-defined TAMARACK Phase 2 mCRPC study data, including predefined landmark primary endpoint of 6-month rPFS rate and updated safety Treatment recently discontinued for TAMARACK mCRPC study participants who remained eligible for further dosing following review of totality of data, including efficacy, and emerging adverse events associated with prolonged exposure and considering potentia ...

Core Insights - MacroGenics, Inc. achieved $100 million in milestones from Incyte Corporation related to the development of ZYNYZ® (retifanlimabdlwr) [1] - ZYNYZ is an intravenous PD-1 inhibitor approved in the U.S. for treating adult patients with metastatic or recurrent locally advanced Merkel cell carcinoma [1] - The collaboration with Incyte began in 2017, and MacroGenics has received a total of $215 million in milestones to date, with potential future milestones totaling $210 million for development and regulatory achievements, and $330 million for commercial milestones [8] Financial Position - MacroGenics expects to report its cash, cash equivalents, and marketable securities balance as of June 30, 2024, around August 6, 2024 [4] - The company anticipates that its cash balance, combined with the recent $100 million milestone and future payments from partners, will support its cash runway into 2026 [4] Strategic Collaborations - MacroGenics generates its pipeline from proprietary next-generation antibody-based technology platforms, leading to strategic collaborations with global pharmaceutical and biotechnology companies [2] - The company has tiered royalties ranging from 15% to 24% on worldwide net sales of ZYNYZ, indicating a revenue-sharing model with Incyte [8]

Under the 2017 collaboration agreement with Incyte, MacroGenics received an upfront payment of $150 million and has achieved a total of $215 million in milestones, including the recent $100 million described above. MacroGenics remains eligible to receive up to a total of $210 million in potential development and regulatory milestones and up to $330 million in potential commercial milestones. MacroGenics receives tiered royalties, which range from 15 to 24 percent, on worldwide net sales of ZYNYZ. About Macr ...